S9912 Combination Chemo in Stage III Ovarian Cancer,
NCT00003896
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, cisplatin, and liposomal doxorubicin in treating women who have undergone surgery for stage III ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
01/02/2013
Locations: Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona +103 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis
NCT00491855
Completed
The goal of this clinical research is to learn acceptable dosages of paclitaxel, oxaliplatin, and Avastin (bevacizumab) that can be given in combination to patients with advanced peritoneal carcinomatosis. The safety of this drug combination will also be studied.
Gender:
ALL
Ages:
All
Trial Updated:
12/31/2012
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Peritoneal Cancer
Register for Updates
Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
NCT00970996
Completed
The goal of this clinical research study is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given in combination with cisplatin, Temodar (temozolomide), interferon alfa-2b, and interleukin-2 (IL-2) to patients with metastatic melanoma. Primary Objective: * The primary objective of the Phase I is to determine the toxicity, safety and the maximum tolerated dose maximum tolerated dose of Abraxane in combination with Cisplatin, Temozolomide, interleukin-2 and interferon a2b in... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/31/2012
Locations: U.T. M.D. Anderson Cancer Center, Houston, Texas
Conditions: Melanoma
Register for Updates
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
NCT00003377
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Paclitaxel and cisplatin may increase the effectiveness of radiation therapy by making the tumor cells more sensitive to the radiation. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of paclitaxel when given with r... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/27/2012
Locations: University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida +12 locations
Conditions: Cervical Cancer
Register for Updates
PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer
NCT00672295
Completed
Primary objective to determine the maximal tolerated (MTD) of dasatinib in combination with paclitaxel and carboplatin during the first cycle of treatment. Secondary objectives to describe the toxicity of this combination of therapy; to describe the pharmacokinetics and pharmacodynamics parameters related to this combination; to describe the clinical activity as defined as the response rate (complete and partial response rate) and progression-free survival \> 6 month; to compare the SRC pathway... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/27/2012
Locations: Moffitt Cancer Center, Tampa, Florida +1 locations
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00003193
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of paclitaxel and radiation therapy plus chemoprotection with amifostine in treating patients with stage III or stage IV head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2012
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Head and Neck Cancer, Oral Complications
Register for Updates
Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma
NCT01182610
Terminated
This is an open-label, Phase II, single-stage study evaluating the use of panitumumab, paclitaxel, carboplatin and 5FU as an induction regimen in subjects with gastroesophageal adenocarcinoma. The expectation is that this combination will both increase potential overall survival by incorporating novel biologic therapy in the neoadjuvant setting and decrease potential surgical mortality by eliminating pre-operative radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2012
Locations: Clopton Clinic, Jonesboro, Arkansas
Conditions: Gastroesophageal Adenocarcinoma, Adenocarcinoma of the Distal Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Adenocarcinoma of the Proximal Stomach
Register for Updates
Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin
NCT00840450
Terminated
This study is designed to determine whether the combination treatment of Paclitaxel and Gleevec on recurrent ovarian cancer patients or other cancers of mullerian origin will generate better clinical response than Paclitaxel alone.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/12/2012
Locations: NYU cancer center, New York, New York
Conditions: Ovarian Cancer
Register for Updates
Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005048
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining estramustine and paclitaxel in treating patients who have prostate cancer that has not responded to hormone therapy.
Gender:
MALE
Ages:
All
Trial Updated:
11/08/2012
Locations: Kaplan Cancer Center, New York, New York +1 locations
Conditions: Prostate Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
NCT00005051
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/08/2012
Locations: Albert Einstein Clinical Cancer Center, Bronx, New York +9 locations
Conditions: Ovarian Cancer
Register for Updates
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00085501
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining more than one chemotherapy drug with a monoclonal antibody may kill more tumor cells. It is not yet known whether cetuximab is more effective when given at the same time a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2012
Locations: Alaska Regional Hospital, Anchorage, Alaska +162 locations
Conditions: Lung Cancer
Register for Updates
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
NCT01604863
Suspended
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or docetaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2012
Locations: Not set, Scottsdale, Arizona +1 locations
Conditions: Cancer
Register for Updates